microbiota transplantation
Gianluca Ianiro, from Gemelli Hospital in Rome, discusses the key determinants of success of FMT in the treatment of C. Difficile infections and other conditions.
The findings of a recent study suggest that microbial consortia such as MET-2 may be effective strategies to keep intestinal pathogens and antibiotic-resistant organisms at bay.
Sara Deleu, researcher at KU Leuven, talks about the role of gut metabolite, as Butyric acid and other compounds, during the fecal microbiota transplantation.
Iris Dothan, from Rabin Medical Center, Israel, talks about the profiling of patient with pouchitis in order to determine the benefits from microbiome manipulation.
Pilar Manrique Ronquillo, Research Scientist at Microviable Therapeuthics, talks about the donor-based microbiome therapeutic products research and development.
The findings of a recent study suggest that FMT is an effective strategy to mitigate the intestinal side effects of cancer immunotherapy.
Lihi Godny, from Rabin Medical Center in Israel, talks about the next steps research has to focus in to improve the FMT efficacy for IBD patients.
The findings of a recent study suggest that the gut microbiota contributes to improve metabolic health after gastric bypass surgery.
Clara Desvignes, Head of Microbiome at VCLS, spoke about the continuously evolving regulatory landscape on Fecal Microbiome Transplant.
Researchers found that the microbiota of the recipient, rather than that of the donor, determines the microbial mix resulting from a fecal transplant.
